Hi Boffin.
I don’t want to make excuses for RAC, but I read the pre clinical results slightly differently.
With CCRCC, the result wasn’t statistically significant, despite showing signs of efficacy, but good rationale for this lack of significance is given, imho.
My reading of the MM, suggests a few different studies were undertaken. However it was “the novel in vivo” which didn’t work, because it sounds like the toxicity of the C’mib killed the mice before they can examine any cardiotoxic properties.
Hence the negatives for me are slow recruiting, hopefully Europe has the power to change this situation, Phil did suggest European delays at AGM given protocol changes to Euro trials.
thx
Please clarify if you think differently.
Ann: Quarterly Activity Report & Appendix 4C, page-59
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |